Psoriatic Arthritis in Well-Controlled HIV: Choosing a Biologic
A woman with eighteen years of well-controlled HIV needs biologic escalation for psoriatic arthritis that hasn't responded to methotrexate. The disagreement isn't whether biologic therapy is safe enough to use — it's which class actually fits her specific disease pattern and safety profile best.
Marlene A., a 55-year-old woman, has sung alto in her church choir every Sunday for over twenty years, and until recently had started rolling her sleeves up during performances without a second thought — something the spreading plaques on her forearms have made her self-conscious about again this year. She has lived with HIV for eighteen years, diagnosed young and started on antiretroviral therapy soon after; she has been on her current regimen, bictegravir/emtricitabine/tenofovir alafenamide, for three years, with an undetectable viral load and a CD4 count that has held steady around 640 the entire time. Apart from HIV she has been healthy, with no history of opportunistic infection at any point in her care.
Plaque psoriasis first appeared four years ago and has been more extensive and harder to control than typical, a pattern well documented in HIV-associated psoriasis. Psoriatic arthritis followed two years later, with peripheral joint swelling, dactylitis of two toes, and Achilles enthesitis that together have made standing through an hour of choir rehearsal genuinely difficult some weeks. Methotrexate at an adequately titrated dose, alongside topical therapy for her skin, has not controlled either her joints or her plaques over the past six months — a clear treatment failure by any standard measure, and the reason biologic escalation is now actually on the table rather than a hypothetical for later.
Her CD4 count and viral load put her outside the range most published case series flag as genuinely risky for biologic therapy in HIV, but that reassurance rests on a literature of small series and registries rather than a randomized trial that could rule out a rare signal. Cepeda and colleagues' 2008 series treated eight HIV-positive patients with TNF inhibitors for rheumatic disease over a mean of twenty-eight months, and reported no clinical adverse effect attributable to the drugs and CD4 counts and viral loads stable in every one of them. What makes that series load-bearing for her rather than merely encouraging is its entry bar: CD4 above 200 and viral load under 60,000. She sits at 640 and undetectable, which is not near that threshold but an order of magnitude clear of it — she is not an extrapolation from that population, she is comfortably inside it. What her team hasn't settled is which biologic class best fits both her joint-and-skin disease pattern and a safety picture where the deepest evidence base and the mechanistically most attractive option for her specific presentation aren't quite the same drug.
Joint rheumatology–infectious disease clinic
I'd start a TNF inhibitor. Cepeda and colleagues followed eight HIV-positive patients on TNF blockade for rheumatic disease across a mean of twenty-eight months and saw no adverse effect attributable to the drugs, with CD4 counts and viral loads stable in all of them; the same group later extended that to seventeen patients through 2021, several on TNF inhibitors more than a decade. What I care about is who they let in: CD4 above 200, viral load under 60,000. Her numbers are 640 and undetectable. She isn't at the edge of that population, she's well inside it.
I don't dispute that the TNF-inhibitor safety data in HIV is the deepest we have, and I'm not arguing against biologic therapy in general. But her disease is doing something specific: dactylitis, enthesitis, and a psoriasis burden that's been more extensive than typical since it started, which is exactly the pattern IL-17A blockade tends to address particularly well, arguably better than TNF inhibition does for this phenotype.
Your safety argument is really an argument from the deepest available case series, not from any actual negative signal for IL-17 inhibitors in HIV specifically — the honest answer is that literature is much thinner, mostly isolated case reports, not that it's worse. I'd still lean toward secukinumab given how well it fits her actual disease pattern, but I recognize we're choosing between a well-mapped and a less-mapped safety profile, not a safe option and a risky one.
Both of you are reasoning from case-series data, and I want to name plainly what that actually is: seventeen patients, accumulated by one group over eighteen years, and no randomized comparison between biologic classes in HIV anywhere in the literature. That's not a reason to avoid biologic therapy — her control is excellent and either class is a defensible choice — but before we add a new immunosuppressive mechanism, I'd want one more attempt at optimizing conventional therapy, adding sulfasalazine to her methotrexate, both to see whether that closes the gap and because it costs her nothing in terms of future biologic options if it doesn't.
Agreed: add sulfasalazine to her existing methotrexate as one further conventional-therapy attempt, reassessing joints and skin at twelve weeks, before starting a biologic. If that combination remains inadequate, proceed to secukinumab first given her enthesitis- and skin-predominant pattern, with adalimumab held as the alternative given its deeper HIV-specific safety experience.
Continued close co-management with her HIV specialist, including a CD4 count and viral load check at the twelve-week visit regardless of which therapy is running by then, was agreed as a standing part of the plan rather than a contingency tied to any one drug choice.